Gilead Sciences, Inc. (GILD)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Gilead Sciences, Inc. (GILD)
Company Performance

Current Price

as of Oct 11, 2024

$84.95

P/E Ratio

103.48

Market Cap

$105.41B

Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Metrics

Overview

  • HQFoster City, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerGILD
  • Price$84.95+0.33%

Trading Information

  • Market Cap$105.41B
  • Float99.79%
  • Average Daily Volume (1m)7,023,120
  • Average Daily Volume (3m)6,444,353
  • EPS$0.84

Company

  • Revenue$27.78B
  • Rev Growth (1yr)5.46%
  • Net Income$1.61B
  • Gross Margin77.78%
  • EBITDA Margin48.67%
  • EBITDA$3.38B
  • EV$104.90B
  • EV/Revenue3.78
  • P/E103.48
  • P/S3.81
  • P/B5.77
Documents